Drug industry demand for ways of improving drug bioavailability is increasing as industry development pipelines fill with BCS Class II and IV compounds.
in-Pharmatechnologist.com will host "Bioavailability Challenge 2013" a free to attend virtual event where you can discuss the latest scientific breakthroughs with experts and meet with fellow researchers and industry peers.
Sign up for the free, virtual event here .
18-Feb-2013 - Aesica and EmulTech claim a new sterile formulation technology could help drugmakers resurrect abandoned projects and extend the lifespan of marketed medicines.
13-Feb-2013 - EpiVax says combining its immune 'off switch’ drugs with Novozymes’ half-life boosting Albufuse platform could deliver a $3bn (€2.2bn) section of the autoimmune disease market.
11-Feb-2013 - Bend Research says collaboration between the Swedish MPA and the US FDA was the reasoning in pursuing GMP from the European body.
04-Feb-2013 - Patheon says expanding its UK facility is necessary in offering its Solupath services to a European and Asian market.
04-Feb-2013 - Solvias has bought quality control services firm Confarma, expanding its analytical offering and adding capacity in several EU markets.
30-Jan-2013 - Taiwanese API maker Scinopharm has taken a first step towards developing its own drug portfolio in partnership with delivery tech firm Foresee Pharmaceuticals.
24-Jan-2013 - Fuisz Pharma says a new tablet design will be of interest to pharma formulators who find esophageal transit failures hard to swallow.
23-Jan-2013 - The cost of proposed new tests designed to ensure levothyroxine tablet quality is a small price to pay for manufacturers to ensure patient safety says the UK MHRA.
15-Jan-2013 - Demand for improved bioavailability solutions will drive drug delivery dealmaking in 2013 according to a pharmaceutical industry expert.
14-Jan-2013 - IDIFarma has been cleared to make commercial batches of high potency tablets and hopes the new capability will attract developers of niche drugs and large CMOs.
10-Jan-2013 - Winning US FDA approval for omega-3 API suppliers like BASF and Chemport is a key milestone for Amarin in 2013 according to CEO Joe Zakrzewski.
03-Jan-2013 - Scientists from targeted therapeutics firm Arrowhead Research claim a vesicle bursting polymer can overcome siRNA delivery difficulties.
03-Jan-2013 - Mitsubishi Chemical Holdings (MCHC) has announced plans to buy the ‘dominant’ pharma-grade HPMC capsule maker Qualicaps as the global gelatin shortage continues.
28-Nov-2012 - Hovione and Solvias have become the latest suppliers to team on drug solubility and bioavailability services in a new deal announced today.
27-Nov-2012 - The bioavailability market lacks a leader that can offer comprehensive solutions according to Merck Millipore, which has set its sights on filling the gap through investments and a new lab....
12-Nov-2012 - Agere Pharmaceuticals has added spray drying to its offering, citing developer demand for bioavailability boosting technologies.
17-Oct-2012 - Bend Research is “actively” hunting new partnerships similar to its recent alliance with Dow.
12-Oct-2012 - Demand for better bioavailability drove another deal this week with Bend Research and Dow teaming up to develop spray drying-based solutions.
08-Oct-2012 - in-Pharmatechnologist.com is going to Madrid, Spain to meet API and excipient makers, Biopharma firms, processing tech developers and contract services organisation gathered for one of the drug industry's biggest trade shows....
01-Oct-2012 - Drug delivery developers could get a boost from a new nanoparticle that can provide deep-tissue imaging.
27-Sep-2012 - API maker Hovione has added particle design to its drug delivery and formulation development offering citing pharma demand.
26-Sep-2012 - Clarus Therapeutics believes it has solved the oral availability problem for testosterone replacement therapy.
29-Aug-2012 - The PRACS Institute has sold its Miami, US facility to a new early-phase focused CRO, CRI Phase I Corporation.
28-Aug-2012 - Bioequivalence and bioavailability (BE/BA) studies for generics firms will have to log details of their sites with the US FDA under new ‘self-identification’ rules.
28-Aug-2012 - CROs conducting bioequivalence and bioavailability (BE/BA) studies for generics firms will have to log details of their sites with the US FDA under new ‘self-identification’ rules.